Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of domestic paliperidone palmitate in schizophrenia
ChiCTR2500109923Phase 4Not yet recruiting
- Sponsor
- The Brain Hospital of Guangxi Zhuang Autonomous Region
- Start
- Sep 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paliperidone palmitate in schizophrenia, sponsored by The Brain Hospital of Guangxi Zhuang Autonomous Region. Primary endpoints: Positive and Negative Syndrome Scale (PANSS) at week 25 and UKU Side-Effect Rating Scale at week 25. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ChiCTR2500109923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109923.